Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
TK Eigentler, JC Hassel, C Berking, J Aberle… - Cancer treatment …, 2016 - Elsevier
PD-1 checkpoint inhibitors are associated with a specific spectrum of immune-related adverse
events. This spectrum is different from toxicities known for kinase inhibitors or cytotoxic …
events. This spectrum is different from toxicities known for kinase inhibitors or cytotoxic …
Melanoma
D Schadendorf, ACJ Van Akkooi, C Berking… - The Lancet, 2018 - thelancet.com
Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of
the disease differ widely across the globe depending on access to early detection and …
the disease differ widely across the globe depending on access to early detection and …
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
…, C Loquai, C Robert, KC Kaehler, C Berking… - PloS one, 2013 - journals.plos.org
Background Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody,
has been approved for the treatment of metastatic melanoma and induces adverse events (AE) …
has been approved for the treatment of metastatic melanoma and induces adverse events (AE) …
Transforming growth factor-β1 increases survival of human melanoma through stroma remodeling
C Berking, R Takemoto, H Schaider, L Showe… - Cancer research, 2001 - AACR
Transforming growth factor (TGF)-β is growth inhibitory for normal epithelial cells and
melanocytes but can stimulate mesenchymal cells. Resistance to its inhibitory effects is …
melanocytes but can stimulate mesenchymal cells. Resistance to its inhibitory effects is …
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
Most patients with BRAF V600 -mutant metastatic melanoma develop resistance to selective
RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF …
RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF …
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
D Lodygin, V Tarasov, A Epanchintsev, C Berking… - Cell cycle, 2008 - Taylor & Francis
Recently, we and others identified the microRNA miR-34a as a target of the tumor suppressor
gene product p53. Ectopic miR-34a induces a G1 cell cycle arrest, senescence and …
gene product p53. Ectopic miR-34a induces a G1 cell cycle arrest, senescence and …
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised …
…, W Hohenberger, N Brockmeyer, C Berking… - The Lancet …, 2016 - thelancet.com
Background Complete lymph node dissection is recommended in patients with positive
sentinel lymph node biopsy results. To date, the effect of complete lymph node dissection on …
sentinel lymph node biopsy results. To date, the effect of complete lymph node dissection on …
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
PA Ascierto, D Schadendorf, C Berking… - The lancet …, 2013 - thelancet.com
Background Patients with melanoma harbouring Val600 BRAF mutations benefit from treatment
with BRAF inhibitors. However, no targeted treatments exist for patients with BRAF wild-…
with BRAF inhibitors. However, no targeted treatments exist for patients with BRAF wild-…
[HTML][HTML] Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
…, MC Kirchberger, T Eigentler, C Berking… - European journal of …, 2016 - Elsevier
Background Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective
treatment option for metastatic melanoma as well as for other cancer entities. They act via …
treatment option for metastatic melanoma as well as for other cancer entities. They act via …
[HTML][HTML] Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
…, MC Kirchberger, T Eigentler, C Berking… - European journal of …, 2016 - Elsevier
Background Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment
option for metastatic melanoma and other cancer entities. They act via blockade of the PD-…
option for metastatic melanoma and other cancer entities. They act via blockade of the PD-…